

New meningitis B vaccines – does the *best* science matter?

LONDON, UK----20th November 2009----ExpertREACT. At the recent Meningitis Research Foundation (MRF) meeting in London (12th & 13th November 2009), new vaccines to protect against *N.meningitidis* serogroup B were discussed. Both Wyeth and Novartis Vaccines are positioning their approaches on “the best science”. **VacZine Analytics** discuss the current issues.

In terms of current *meningococcal* disease burden, the statistics related to serogroup B are convincing when making arguments in support of new meningitis vaccines.....

CONTINUED.....

*****NOTE***** This article is available only on a “pay per view” basis or to individual existing **VacZine Analytics** clients who have purchased **MarketVIEW**: meningitis ACWY vaccines (US Version), CAT No: VAMV009, published December 2009.


Please visit www.vaccine-analytics/products-expertreact



References and Notes:

- 1) Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report. Emerging Infections Program Network. Neisseria meningitidis, 1999-2007. Available at: <http://www.cdc.gov>. Accessed November 2009.
- 2) Gray S.J., et al. Epidemiology and Surveillance of meningococcal disease in England and Wales. Poster Presentation at Meningitis Research Foundation (MRF) meeting in London (12th & 13th November 2009)
- 3) Murphy E., et al. Sequence diversity of factor H binding protein vaccine candidate in epidemiologically relevant strains of Neisseria meningitidis serogroup B. JID 2009; 200:379-389
- 4) Kelly C., et al. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol. 2007; 166(7):817-823
- 5) Islam et al., fHBP Variation and Expression is Independent of Age, Gender and Disease Outcome for Meningococcal Serogroup B Disease. Poster Presentation at Meningitis Research Foundation (MRF) meeting in London (12th & 13th November 2009)
- 6) Findlow J., et al. Immunogenicity of an investigational recombinant meningococcal vaccine with and without outer membrane vesicles, against a serogroup B strain representative of the Normandy Outbreak. Poster Presentation at Meningitis Research Foundation (MRF) meeting in London (12th & 13th November 2009)

A printable version of this article is available upon request.

VacZine Analytics^(R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics^(R) and “the spiral logo” are UK Registered Trademarks, 2009





A printable version of this article is available upon request.

VacZine Analytics[®] is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics[®] and “the spiral logo” are UK Registered Trademarks, 2009

© 2009 VacZine Analytics. All rights reserved.